20 Years and Counting as a CPI: A Pennsylvania Principal Investigator Shares His Story
Dr. Kivitz of Altoona Arthritis & Osteoporosis Center has been deeply involved in clinical research for decades, witnessing and contributing to meaningful advancements in rheumatology. His journey began during a period of rapid expansion in the field, particularly with the introduction of COX-2 inhibitors, which fueled a growing demand for clinical trial sites. His practice quickly became a hub for this research, and later, for the development and implementation of biologic therapies for inflammatory rheumatic diseases, starting in the late 1990s and continuing to the present day.
Today, Dr. Kivitz practices alongside three other Rheumatology physicians and six Advanced Practice Providers at Altoona Arthritis & Osteoporosis Center. The practice operates in conjunction with the Altoona Center for Clinical Research,which has expanded its scope over the years to include trials in areas beyond rheumatology,such as weight loss,hyperlipidemia,vaccines,and smoking cessation.
Practicing in Altoona, Pennsylvania – a more rural region – presents a unique surroundings for clinical trials. Dr. Kivitz notes that patients in the area are generally accustomed to traveling for specialized healthcare, a contrast to the potential reluctance seen in larger metropolitan areas. Furthermore, the region benefits from easier navigation compared to congested cities.
Driven by a desire to strengthen relationships with sponsors as his involvement in trials grew, Dr. Kivitz initially pursued clinical investigator certification more than 20 years ago.He first earned certification through the Drug Information Association (DIA) and later transitioned to the Association of Clinical Research Professionals (ACRP), where he remains certified today. While he acknowledges certification may not be a primary factor in participant recruitment, he views it as a commitment to upholding high standards.
For dr. kivitz, the most rewarding aspect of clinical research is witnessing the approval of new medications, having contributed to the development of every Rheumatology medication currently available. He frequently enough had the opportunity to treat patients with these therapies years before they received U.S. Food and Drug Governance approval.
He defines being a strong Certified Principal Investigator (CPI) as a dedication to continuous learning, adapting to increasingly complex protocols, and maintaining the highest standards in clinical research. While widespread recognition of the CPI certification may still be evolving, Dr. Kivitz values it as a personal commitment to excellence and hopes for greater industry recognition in the future.
